Core Points - The core viewpoint of the article is that BGI Genomics (300676) announced the preliminary transfer price of shares at 44.10 yuan per share based on the inquiry subscription situation on September 15 [1] Group 1 - BGI Genomics is conducting a non-public transfer of shares, which will not be executed through centralized bidding or block trading methods [1] - The shares acquired through the inquiry transfer cannot be transferred by the acquirer within six months after the acquisition [1]

Core Viewpoint - The company BGI Genomics announced a preliminary transfer price of 44.1 yuan per share for its non-public share transfer, which is based on the inquiry subscription situation as of September 15, 2025 [1] Summary by Relevant Categories Share Transfer Details - The share transfer is a non-public transfer and will not be conducted through centralized bidding or block trading methods [1] - The shares acquired through this inquiry transfer cannot be transferred by the acquirer within six months after the acquisition [1] Investor Profile - The acquirer of the shares will be institutional investors who possess the necessary pricing capability and risk tolerance [1]

证券代码：300676 证券简称：华大基因 公告编号：2025-051 深圳华大基因股份有限公司 股东询价转让定价情况提示性公告 股东深圳华大基因科技有限公司保证向深圳华大基因股份有限公司提供的信息内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据2025年9月15日询价申购情况，深圳华大基因股份有限公司（以下简称公司） 股东深圳华大基因科技有限公司询价转让（以下简称本次询价转让）初步确定的转 让价格为44.10元/股； 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式进行，不属 于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转 让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 深圳华大基因股份有限公司董事会 2025 年 9 月 15 日 （一）本次询价转让尚存在拟转让股份被司法冻结、扣划等风险。询价转让的最终 结果以中国证券登记结算有限责任公司深圳分公司最终办理结果为准。 （二）本次询价转让不会导致公司控制权发 ...

Group 1 - On September 15, BGI Genomics executed a block trade of 522,100 shares, with a transaction value of 25 million yuan, accounting for 2.98% of the total trading volume for that day [1][2] - The transaction price was 47.88 yuan, representing a 10% discount compared to the market closing price of 53.2 yuan [1][2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司持股5% 以上股东深圳生华投资企业（有限合伙）（以下简称生华投资）的通知，获悉生华 投资将其持有的部分公司股份办理了解除质押及再质押，相应的解除质押及再质押 登记手续已通过中国证券登记结算有限责任公司深圳分公司办理完毕。现将具体内 容公告如下： 一、股东股份解除质押及再质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所持股 | 占公司 | 质押起始 | 质押解除日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股份数量 | | 总股本 | | | 质权人 | | | 大股东及其 | | 份比例 | | 日期 | 期 | | | | 一致行动人 | （股） | | 比例 | | | | | 深圳生华投资 | | | | | | | 中国银行股份 | | 企业（有限合 | 否 | 4,850,000 | 15.23% | 1.16% | 2024/ ...

Core Viewpoint - The medical sector is experiencing significant growth, with the largest medical ETF in A-shares (512170) showing a notable increase and attracting substantial investment recently [1][3]. Group 1: ETF Performance - The medical ETF (512170) rose over 1% on September 15, with a trading volume exceeding 460 million yuan [1]. - The ETF has attracted a total of 380 million yuan over four consecutive days leading up to September 12, bringing its total size to 27.584 billion yuan, ranking first among similar ETFs [1]. Group 2: Stock Performance - CXO stocks performed well, with notable gains from companies such as Zhaoyan New Drug, which hit the daily limit, and Kanglong Chemical and Jiuzhou Pharmaceutical, with increases of 6.37% and 3.95% respectively [3]. - Conversely, companies like BGI Genomics, Weining Health, and BGI Intelligent Manufacturing saw declines of 2.91%, 2.38%, and 1.93% respectively [3]. Group 3: Industry Outlook - According to Wanlian Securities, the overall revenue of the medical R&D outsourcing CXO sector is expected to grow by 13.77% year-on-year in the first half of 2025, with net profit attributable to shareholders increasing by 63.82% [3]. - The period from September 1 to 15, 2025, saw over 400 new Class I drugs in clinical trials and more than 1,800 Class II and III medical devices approved for market [3]. - Xinda Securities highlighted that the recovery of in-hospital procurement in the high-end medical device sector is driving growth, alongside a gradual recovery in consumer medical demand and increased penetration of high-end consumables [3]. Group 4: ETF Composition - The ETF (512170) and its off-market linked fund (012323) passively track the CSI Medical Index, with the top ten weighted stocks including WuXi AppTec, Mindray Medical, and United Imaging Healthcare [4][5].

核酸分析技术已成为生命科学研究与精准医疗应用的核心驱动力。在基因组学、疾病诊断、新药研发、环境监测、食品 安全等诸多领域，核酸分析技术正不断推动检测精度提升、分析方法创新和仪器设备智能化发展，为人类健康与生物安 全提供关键技术支撑。 为促进核酸分析领域的学术交流、技术创新与产学研协同，由杨朝勇教授（厦门大学）牵头，韩达（中国科学院杭州医 学研究所）、刘震（南京大学）、孙佳姝（国家纳米科学中心）、徐讯（华大基因）、赵永席（西安交通大学）等知名 学 者 共 同 组 建 中 国 分 析 测 试 协 会 核 酸 分 析 分 会 。 现 面 向 社 会 各 界 公 开 征 集 分 会 Logo设 计 ， 诚 挚 邀 请 海 内 外 科 研 工 作 者、设计师、企业及创新团队积极参与，共同打造一个兼具科学内涵与视觉美感的标识。 摘要 ： 为促进核酸分析领域的学术交流、技术创新与产学研协同，由杨朝勇教授牵头，韩达、刘震、孙佳姝、徐讯、赵永席等知名 学者共同组建中国分析测试协会核酸分析分会，现面向社会各界公开征集分会Logo设计。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可 ...

Core Insights - The recent招商推介会 in Xuzhou's Gonglu District aims to enhance economic development through collaboration with local business associations and the establishment of a regular cooperation mechanism for project attraction and talent introduction [1] Group 1: Economic Development Strategies - The 铜沛街道 focuses on improving economic quality and efficiency through a three-pronged approach: "筑巢引凤" (building nests to attract phoenixes), "招新引优" (attracting new and quality enterprises), and "有中生新" (creating new from existing) [1] - The street has implemented the "党建领航产业向新蝶变" project to transform organizational advantages into development momentum, addressing issues like underutilization of building resources and fragmented investment attraction [1] Group 2: Infrastructure and Commercial Development - The 凯旋门商业综合体, a new commercial complex, has been completed and includes various well-known brands, aiming to enhance the modern service industry in the area [2] - The 九里峰景商业综合体 and 市政建设科研大厦 are undergoing transformations to optimize office space and attract quality enterprises, with 九里峰景 generating an annual tax revenue of approximately 910 million and 市政建设科研大厦 achieving an annual output value of 1.45 billion [2][3] Group 3: Investment Attraction and Industry Growth - The street has established a "全员全域招商" (full participation in investment attraction) strategy, forming a team of over 50党员 to target over 30 potential enterprises, enhancing the quality of investment [4] - New projects like 江苏海康博瑞电子有限公司 are thriving, with a goal of producing 200 million RFID electronic tags this year, indicating a shift towards high-end and quality investment [4] Group 4: Service Optimization and Enterprise Support - The 铜沛街道 has improved its enterprise service mechanism, ensuring timely support for over a thousand local businesses, which has led to the establishment of new projects and the transformation of existing enterprises [7] - The street has added five scale enterprises and seven "准规模" enterprises this year, with plans to apply for high-tech enterprise status for four companies, indicating a growing industrial base [8]

Group 1 - Baiyang Pharmaceutical plans to strategically invest in Jikun Pharmaceutical by acquiring a 24% stake, securing rights to the innovative drug for pulmonary fibrosis, JK1033, and gaining priority purchase rights for all global compound rights of Jikun Pharmaceutical's products [1] - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission to issue shares and purchase stakes in Hunan Qianjin Xiangjiang Pharmaceutical (28.92%) and Hunan Qianjin Xieli (68%), enhancing its collaboration in the western medicine sector and supporting its "one main, two auxiliary" strategy [2] - BGI Genomics' major shareholder, Shenzhen BGI Genomics Technology Co., plans to transfer 4% of its shares (16.73 million shares) through a pricing inquiry to meet funding needs for cutting-edge technology incubation in cell and spatiotemporal genomics [3] Group 2 - Suoyuan Biotech's key ENLIGHTEN trial results were published in the prestigious journal JAMA Psychiatry, showing significant efficacy of DB104 (Liafensine) in treatment-resistant depression patients with the ANK3 biomarker, marking a breakthrough in precision medicine for mental health [4] - Betta Pharmaceuticals intends to list on the Hong Kong Stock Exchange, reporting a revenue of 1.731 billion yuan in the first half of 2025, a 15.37% increase, but a net profit decline of 37.53% to 140 million yuan, indicating challenges despite growth in revenue [5]

Group 1: Capital Increase, Mergers, and Acquisitions - Aerospace Electronics plans to swap assets worth 800-1,000 million to enhance its industrial chain [1] - Tianhua New Energy intends to acquire 75% equity of Suzhou Tianhua Times for 1,254 million, transferring control of lithium resource investment to the listed company [1] - Tuojing Technology aims to raise no more than 4,600 million through a private placement for high-end semiconductor equipment industrialization projects; additionally, the Big Fund Phase III will invest no more than 450 million in Tuojing Technology, becoming its second-largest shareholder [1] - Qianjin Pharmaceutical's plan to increase capital for acquiring 28.92% equity of Hunan Qianjin Xiangjiang Pharmaceutical and 68% equity of Qianjin Xieli Pharmaceutical has been approved [1] Group 2: Share Buybacks and Equity Transfers - Yishitong plans to repurchase shares worth 30-55 million, with a maximum price of 40.69 yuan per share [2] - Shanghai Yizhong intends to repurchase shares worth 30-35 million, with a maximum price of 106.08 yuan per share [3] - Chuangyuan Co. plans to repurchase 2.8-3.7 million shares, with a maximum price of 41.5 yuan per share, for future employee stock ownership plans [3] - JinkoSolar's shareholder plans to transfer 4% of shares through inquiry [4] - Huading Co.'s shareholder intends to transfer a total of 9.26% of shares through public solicitation [5] - BGI's shareholder plans to transfer 4% of shares through inquiry [6] Group 3: External Investments and Daily Operations - Nanfeng Co. plans to invest 50 million in fixed assets for a 3D printing service project [7] - Jingjiawei signed a strategic cooperation agreement with Anchaoyun Software [8] - Longjing Environmental Protection's wholly-owned subsidiary acquired 80% of GML, gaining development rights for a 140MW hydropower project in the Democratic Republic of the Congo, with a total investment of approximately 399 million [8] - Boshi Co. signed a contract with Guoneng Yulin for a chemical packaging operation project, with a contract amount of approximately 235 million [8] - Zhongchao Holdings signed a strategic cooperation agreement with Hefei Intelligent Robot Research Institute [9] - Dongcai Technology's high-speed electronic resin has been supplied to major server systems including Nvidia [10] - Chiplink Integration plans to transfer some technology and equipment for no less than 458 million [10] - Huibo Yuntong's related party plans to acquire 22.0875% of Baode Computing [10] - Shanghai Mechanical and Electrical plans to transfer 67% equity of its subsidiary Simik Welding Materials [10] - Wan'an Technology intends to acquire 2.72% equity of Tongchuan Technology through capital increase [10] - Guodun Quantum plans to sign two sales contracts with China Telecom Quantum Group [10] - Sinopec Oilfield Services' wholly-owned subsidiary is expected to win a construction project worth 858 million from the National Pipeline Group [11]